Hypertension and renal dysfunction in long-term liver transplant recipients

Liver Transplantation

Volumn 7, Issue 11 SUPPL. 1, 2001, Pages s22-s26

  Gonwa, Thomas A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLOSPORIN A; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; IMMUNOSUPPRESSIVE AGENT; ISRADIPINE; MINOXIDIL; NICARDIPINE; NIFEDIPINE; TACROLIMUS;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CONTRAINDICATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; RISK; SURVIVAL RATE;

EID: 0035184298     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.28511     Document Type: Article

References (31)

1. Long-term medical complications in patients surviving ≥ 5 years after liver transplant
2. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients
3. Long-term survival after liver transplantation in 4000 consecutive patients at a single center
4. Nephrotoxicity of cyclosporine in liver transplantation
5. Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporine treatment: Beneficial effects of low doses in early post transplantation period
6. Cyclosporine induced chronic nephropathy. An obliterative microvascular renal injury
7. Impact of pretransplant renal function on survival after liver transplantation
8. Hepatorenal syndrome: Combined liver kidney transplants versus isolated liver transplants
9. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation
10. Nephrotoxicity following orthotopic liver transplantation: A comparison between cyclosporine and FK506
11. Chronic renal failure following liver transplantation
12. End stage renal disease (ESRD) following orthotopic liver transplantation (OLTX) utilizing calcineurin based immunotherapy: Risk of development and treatment
13. Universal occurrence of glomerular abnormalities in patients receiving liver transplants
14. Persistent glomerular abnormalities following orthotopic liver transplantation
15. Hepatorenal syndrome
16. Experience with the use of sirolimus in liver transplantation-Use in patients for whom calcineurin inhibitors are contraindicated
17. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not results in sustained improvement in kidney function and causes cellular and ductopenic rejection
18. Conversion from cyclosporine A to mycophenolate mofetil in liver transplantation recipients with renal function impairment
19. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil
20. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
21. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
22. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated transplant recipients
23. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats
24. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation
25. Cyclosporine A upregulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells
26. Post transplantation hypertension related to calcineurin inhibitors
27. Long term use of FK506 in living related transplantation
28. Renal complications and development of hypertension in the European study of FK506 and cyclosporin in primary liver transplant recipients
29. Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK506)
30. Early steroid withdrawal in liver transplantation is safe and beneficial
31. Steroid withdrawal in liver transplantation: Benefits, risks, and unanswered questions